Long‐Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab‐Based Frontline Therapy

Long‐Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab‐Based Frontline Therapy | ReachRx